MREO (Mereo BioPharma Group plc American Depositary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by MREO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | Annalisa Jenkins | Director | A | — | — |
| 2026-02-27 | DEEPIKA PAKIANATHAN | Director | A | — | — |
| 2026-02-27 | Daniel Shames | Director | A | — | — |
| 2026-02-27 | Anders Ekblom | Director | A | — | — |
| 2026-02-27 | MICHAEL S WYZGA | Director | A | — | — |
| 2026-02-27 | Pierre Jacquet | Director | A | — | — |
| 2026-02-27 | Jeremy Bender | Director | A | — | — |
| 2026-02-27 | Marc J Yoskowitz | Director | A | — | — |
| 2026-02-02 | Christine Ann Fox | Chief Financial Officer | A | — | — |
| 2026-02-02 | Charles Sermon | General Counsel | A | — | — |
| 2026-02-02 | Alexandra Hughes-Wilson | See Remarks | A | — | — |
| 2026-02-02 | John A. Lewicki | Chief Scientific Officer | A | — | — |
| 2026-02-02 | Denise Scots-Knight | Chief Executive Officer | A | — | — |
| 2025-02-06 | DEEPIKA PAKIANATHAN | Director | A | — | — |
| 2025-02-06 | Anders Ekblom | Director | A | — | — |
| 2025-02-06 | Pierre Jacquet | Director | A | — | — |
| 2025-02-06 | MICHAEL S WYZGA | Director | A | — | — |
| 2025-02-06 | Marc J Yoskowitz | Director | A | — | — |
| 2025-02-06 | Daniel Shames | Director | A | — | — |
| 2025-02-06 | Jeremy Bender | Director | A | — | — |
| 2025-02-06 | Annalisa Jenkins | Director | A | — | — |
| 2025-01-28 | Alexandra Hughes-Wilson | See Remarks | A | — | — |
| 2025-01-28 | Christine Ann Fox | Chief Financial Officer | A | — | — |
| 2025-01-28 | Denise Scots-Knight | Chief Executive Officer | A | — | — |
| 2025-01-28 | Charles Sermon | General Counsel | A | — | — |
| 2025-01-28 | John A. Lewicki | Chief Scientific Officer | A | — | — |
| 2024-09-16 | Denise Scots-Knight | Chief Executive Officer | Sell | — | — |
| 2024-09-16 | John A. Lewicki | Chief Scientific Officer | Sell | — | — |
| 2024-09-16 | Christine Ann Fox | Chief Financial Officer | Sell | — | — |
| 2024-09-16 | Charles Sermon | General Counsel | Sell | — | — |
| 2024-09-16 | Alexandra Hughes-Wilson | See Remarks | Sell | — | — |
| 2024-09-13 | Christine Ann Fox | Chief Financial Officer | M | — | — |
| 2024-09-13 | Denise Scots-Knight | Chief Executive Officer | M | — | — |
| 2024-09-13 | Charles Sermon | General Counsel | M | — | — |
| 2024-09-13 | Alexandra Hughes-Wilson | See Remarks | M | — | — |
| 2024-09-13 | John A. Lewicki | Chief Scientific Officer | M | — | — |
| 2024-08-23 | DEEPIKA PAKIANATHAN | Director | MIXED | — | — |
| 2024-06-27 | Christine Ann Fox | Chief Financial Officer | Sell | — | — |
| 2024-06-27 | Denise Scots-Knight | Chief Executive Officer | Sell | — | — |
| 2024-06-27 | Alexandra Hughes-Wilson | See Remarks | Sell | — | — |
| 2024-06-27 | John A. Lewicki | Chief Scientific Officer | Sell | — | — |
| 2024-06-27 | Charles Sermon | General Counsel | Sell | — | — |
| 2024-06-25 | Alexandra Hughes-Wilson | See Remarks | M | — | — |
| 2024-06-25 | Christine Ann Fox | Chief Financial Officer | M | — | — |
| 2024-06-25 | Charles Sermon | General Counsel | M | — | — |
| 2024-06-25 | John A. Lewicki | Chief Scientific Officer | M | — | — |
| 2024-06-25 | Denise Scots-Knight | Chief Executive Officer | M | — | — |
| 2024-06-17 | MICHAEL S WYZGA | Director | A | — | — |
| 2024-06-17 | Rubric Capital Management LP | 10%+ Owner | A | — | — |
| 2024-06-17 | Jeremy Bender | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 868,967 | — |
| — | General Counsel | 219,061 | — |
| — | See Remarks | 134,483 | — |
| — | Chief Financial Officer | 108,443 | — |
| — | Director | 105,244 | — |
| — | Chief Scientific Officer | 92,826 | — |
| — | Director | 25,050 | — |
| — | Director | 12,550 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MREO quote page; the site-wide leaderboard is on the insider transactions hub.